B-hPD-1/hPD-L1/hC5AR1 mice_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

한국

미국

일본

중국

영국

호주

프랑스

독일

이탈리아

싱가포르

인도

러시아

캐나다

스위스

기타 국가

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

동물/세포 모델

동물/세포모델

Humanized Mouse Models

GPCR Humanized Mice

Text

B-hPD-1/hPD-L1/hC5AR1 mice

Strain Name	C57BL/6-Pdcd1^{tm1(PDCD1)Bcgen} Cd274^{tm1(CD274)Bcgen} C5ar1^{tm1(C5AR1)Bcgen}/Bcgen	Common Name	B-hPD-1/hPD-L1/hC5AR1 mice
Background	C57BL/6	Catalog number	131216
Related Genes	PDCD1: CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1; CD274: B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1; C5AR1: C5A, C5AR, C5R1, CD88
NCBI Gene ID	18566,60533,12273

Protein expression analysis

from clipboard

Strain specific PD-1, PD-L1, C5AR1 expression analysis in homozygous B-hPD-1/hPD-L1/hC5AR1 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H) for PD-1 and PD-L1 expression analysis; Bone marrow was collected from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H) for C5AR1 expression analysis. Analyses were performed by flow cytometry with species-specific anti-PD-1, anti-PD-L1 and anti-C5AR1 antibody. Mouse PD-1, PD-L1, C5AR1 were detectable in wild-type C57BL/6 mice. Human PD-1, PD-L1, C5AR1 were exclusively detectable in homozygous B-hPD-1/hPD-L1/hC5AR1 mice but not in wild-type mice.

Analysis of leukocytes cell subpopulation in spleen

from clipboard

Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in spleen

from clipboard

Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in lymph node

Analysis of lymph node leukocyte subpopulations by FACS. Lymph nodes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in lymph node

from clipboard

Analysis of lymph node T cell subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in blood

Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in blood

Analysis of blood T cell subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.

Antibody binding assay

from clipboard

Antibody binding analysis of B-hPD-1/hPD-L1/hC5AR1 mice by FACS. Splenocytes were isolated from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H). Anti-hC5AR1 antibody avdoralimab (in house) can bind CD11b+ cells in spleen of B-hPD-1/hPD-L1/hC5AR1 mice. But the antibody can not bind the cells in spleen of wild-type C57BL/6 mice. Thus the anti-hC5AR1 antibody can specifically bind cells of B-hPD-1/hPD-L1/hC5AR1 mice.

In vivo efficacy of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody

from clipboard

Antitumor activity of combination of anti-human PD-1 antibody (pembrolizumab, in house) and anti-human C5AR1 antibodies (avdoralimab, in house) in B-hPD-1/hPD-L1/hC5AR1 mice. (A) combination of anti-human PD-1 antibody and anti-human C5AR1 antibody inhibited B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hC5AR1 mice (female, 7-9-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with anti-human PD-1 antibody and anti-human C5AR1 antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human C5AR1 antibody were efficacious in controlling tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice, demonstrating that the B-hPD-1/hPD-L1/hC5AR1 mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody. Values are expressed as mean ± SEM.

In vivo efficacy of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody

from clipboard

Antitumor activity of combination of anti-human PD-1 antibody (pembrolizumab, in house) and anti-human C5AR1 antibodies (avdoralimab, in house) in B-hPD-1/hPD-L1/hC5AR1 mice. (A) combination of anti-human PD-1 antibody and anti-human C5AR1 antibody inhibited B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hC5AR1 mice (female, 5-8-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with anti-human PD-1 antibody and anti-human C5AR1 antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human C5AR1 antibody were efficacious in controlling tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice, demonstrating that the B-hPD-1/hPD-L1/hC5AR1 mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody. Values are expressed as mean ± SEM.